Filing Analysis
Korro Bio, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. The stockholders elected two Class I directors, approved executive compensation in a non-binding vote, and ratified the appointment of Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- The CEO is currently serving as the Interim CFO, which may indicate a vacancy in a key financial leadership role.
📋 Key Facts
- Nessan Bermingham and Rachel Meyers were elected as Class I directors for three-year terms ending in 2029.
- Executive compensation was approved via a non-binding advisory vote with 9,009,739 votes 'For' and 27,988 votes 'Against'.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 10,917,621 votes 'For'.
- The filing was signed by Ram Aiyar, who serves as President, CEO, and Interim CFO.
Korro Bio, Inc. announced the addition of KRRO-111, a new therapeutic candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD), to its development pipeline. The company also updated its corporate presentation slides for upcoming investor and analyst meetings.
📋 Key Facts
- Announced the addition of KRRO-111 to its therapeutic pipeline on May 19, 2026.
- KRRO-111 is being developed for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD).
- Updated corporate presentation slides were filed as Exhibit 99.2 for use in investor and analyst meetings.
- The report was filed under Item 8.01 (Other Events) and signed by Ram Aiyar, President, CEO, and Interim CFO.
Korro Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1.
🚩 Red Flags
- The CEO (Ram Aiyar) is also serving as the Interim CFO, indicating a vacancy in a key executive financial position.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 7, 2026.
- Ram Aiyar is currently serving as President, Chief Executive Officer, and Interim Chief Financial Officer.
Korro Bio, Inc. announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
🚩 Red Flags
- CEO Ram Aiyar is also serving as Interim CFO, indicating a lack of a dedicated permanent Chief Financial Officer.
📋 Key Facts
- Financial results reported for the full year ended December 31, 2025
- Report filed on March 12, 2026
- Ram Aiyar is currently serving as President, CEO, and Interim Chief Financial Officer
- Information furnished under Item 2.02 is not deemed 'filed' for Section 18 liability purposes
Korro Bio, Inc. entered into a subscription agreement for a private placement (PIPE) to raise approximately $85.0 million in gross proceeds through the sale of common stock and pre-funded warrants. The financing, led by Venrock Healthcare Capital Partners, is expected to extend the company's cash runway into the second half of 2028.
🚩 Red Flags
- The CEO is currently serving as the Interim CFO, indicating a vacancy in a key executive position.
- The registration rights agreement includes liquidated damages provisions if deadlines for filing or effectiveness are not met.
- The offering is a private placement (PIPE), which is typically dilutive to existing shareholders.
📋 Key Facts
- Agreement to sell 4,501,928 shares of common stock at $11.11 per share.
- Agreement to sell 3,148,836 pre-funded warrants at $11.109 per warrant with an exercise price of $0.001.
- Gross proceeds of approximately $85.0 million before commissions and expenses.
- Participation from institutional investors including Venrock, ADAR1 Capital Management, Balyasny Asset Management, and New Enterprise Associates.
- Preliminary cash, cash equivalents, and marketable securities of $85.2 million as of December 31, 2025.
- Company must file a resale registration statement within 30 days of closing and cause it to be effective within 60-90 days.
- Ram Aiyar is currently serving as both President/CEO and Interim Chief Financial Officer.